Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Beyondspring Inc (NQ: BYSI )

11.06 USD -0.71 (-6.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 16, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 362,544
Open 12.00
Bid (Size) 10.50 (1)
Ask (Size) 10.80 (144)
Prev. Close 11.77
Today's Range 10.57 - 12.00
52wk Range 9.240 - 18.10
Shares Outstanding 39,106,476
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update
From GlobeNewswire News Releases
BeyondSpring to Host First Quarter Financial Results and Corporate Update Conference Call on June 16, 2021
From GlobeNewswire News Releases

Performance

YTD
-9.05%
-9.05%
1 Month
+14.02%
+14.02%
3 Month
-12.08%
-12.08%
6 Month
-2.30%
-2.30%
1 Year
-35.51%
-35.51%

More News

Read More
BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annua
From GlobeNewswire News Releases
BeyondSpring Announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data Showing Plinabulin, in Combination with Pegfilgrastim, Reverses the Immune-Suppressive Effects of Pegfilgrastim
From GlobeNewswire News Releases
BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induc
From GlobeNewswire News Releases
BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with
From GlobeNewswire News Releases
BeyondSpring Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)
From GlobeNewswire News Releases
BeyondSpring to Present at the Jefferies Virtual Healthcare Conference on June 3, 2021
From GlobeNewswire News Releases
BeyondSpring Presents Phase 1 Data on the Anti-Cancer Effect of Plinabulin in Combination with Checkpoint Inhibitors in SCLC at the American Society of Clinical Oncology (ASCO) Annual Meeting
From GlobeNewswire News Releases
BeyondSpring to Present at the Bank of America Securities 2021 Health Care Conference on May 13, 2021
From GlobeNewswire News Releases
BeyondSpring Files 2020 Annual Report on Form 20-F
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.